Williams Cancer Institute

The Impact of ARID1A Gene Mutation on Cancer Immunotherapy

Immunotherapy has transformed cancer treatment in recent years, shifting the focus from directly targeting tumors to mobilizing the patient’s immune system to do so. This strategy has proven particularly effective for certain hard-to-treat cancers. However, fewer than half of all patients respond favorably to current immunotherapies, highlighting the urgent need to identify biomarkers that can […]

MAO Inhibitors as Novel Cancer Immunotherapy Candidates

The serotonin signaling pathway has been extensively studied in neurons for decades. Serotonin, released by presynaptic neurons, communicates feelings of happiness and other behavioral changes by binding to the 5-hydroxytryptamine receptor (5-HTR) on postsynaptic neurons. After signaling, serotonin is reuptaken by presynaptic neurons to prevent overstimulation of 5-HTR, and is then broken down by the […]

Cracking the Code: Unraveling Tumors’ Immune Evasion Tactics

In the ongoing battle against cancer, understanding how tumors evade immune responses is crucial. Researchers from the Technical University of Munich (TUM) and the Ludwig-Maximilians-Universität München (LMU) Hospital have made a significant breakthrough in this area, revealing the intricate mechanisms through which tumors actively thwart the body’s immune defenses. Published in the prestigious journal Nature, […]

Innovative Intraperitoneal Immunotherapy Shows Promise in Recurrent Gynecological Cancers

A recent study conducted by Knisely et al focused on improving treatment outcomes for recurrent gynecological cancers with peritoneal metastases. Traditional intraperitoneal chemotherapy has demonstrated superiority over intravenous chemotherapy in treating advanced ovarian cancer. However, intravenous immunotherapy with immune checkpoint inhibitors has shown limited effectiveness in recurrent ovarian, cervical, and endometrial cancers. To address this, […]

Towards Targeted Triumph: SYNC-T™ Shows Promise in Treating Advanced Prostate Cancer

SYNC-T™, an innovative in situ personalized therapy developed by SYNCROMUNE® Inc., has shown promising results in the treatment of metastatic castrate-resistant prostate cancer (mCRPC), as announced at the American Association for Cancer Research (AACR) Annual Meeting 2024. The Phase 1 trial revealed an impressive overall response rate (ORR) of 85%. Dr. James Armitage, Chairman of […]

Young Onset Cancer: Unveiling the Mystery of Accelerated Aging

Expert researchers have attributed an ‘explosion’ of cancer cases among younger people to something ‘highly concerning’, according to a recent study. While cancer is typically associated with older individuals, there has been a rise in the number of cancer cases diagnosed among younger demographics in recent years. This increase is reportedly due to “accelerated aging” […]

SYNC-T Technology: Advancements in Cancer Therapy

Syncromune® Inc., a leading biopharmaceutical company, has unveiled promising outcomes from its Phase 1 trial of SYNC-T™ therapy at the American Association for Cancer Research (AACR) Annual Meeting 2024. SYNC-T, a cutting-edge personalized treatment tailored for solid tumor cancers, demonstrated an impressive overall response rate (ORR) of 85% in patients with metastatic castrate-resistant prostate cancer […]